UK Biotech Not Impressed By Govt’s Response To MPs’ Brexit Concerns
The UK government has published its response to the concerns raised by a parliamentary health committee about the impact of Brexit on medicines and medical devices. However, the response is lacking in detail, and the biotech industry says it does not provide the information companies need to be able to plan for the future.
You may also be interested in...
The BioIndustry Association is planning to contribute to a UK parliamentary inquiry into the likely effects of a “no-deal” Brexit on healthcare and medicines supply, and has urged companies to notify the government of the state of their contingency plans.
The UK will be able to play a full part in the EU’s new clinical trial system if the legislation takes effect during a Brexit transition period. However, if there is no transition period, the extent of its future participation in the new trials portal is far from certain.
A report from the UK House of Commons business committee on its inquiry into the impact of Brexit on the pharma sector has flagged up the multiple challenges facing companies and regulators.